Seeking Alpha
20 Mar 2026, 17:55 UTC · 26w ago
Verdict
Headline takes no side. We score ASMB +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Gilead has licensed Assembly Biosciences' HPI program, triggering an immediate $35M payment and up to $330M in potential milestones.
So whatDirect non-dilutive funding and validation from a major industry player significantly reduce financial risk and increase valuation.
More positive than 99% of claims this week
ABI-6250 is positioned to be the first oral HDV therapy, supported by positive phase 1a data and a favorable safety profile.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Phase 2 trials for the HPI program and ABI-6250 are expected to begin by the end of 2026.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Company received a $35M payment and potential milestones from Gilead, with positive Phase 1a data for its HDV candidate.
More positive than 53% of ticker scores this week
Gilead is expanding its portfolio by licensing Assembly Biosciences' HPI program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
−12.9%
Price is moving against the score
$23.97 vs $27.51 close before publication (Mar 19) · not market-adjusted
ASMB chart →
